Jaguar Health's Q3 2025 results showed stable revenue compared to the prior year and slightly reduced net loss. Modest gains in prescription product sales were noted, while R&D and administrative expenses saw small changes. A potential new treatment for MVID is progressing with FDA engagement.

Jaguar Health delivered approximately $3.0 million in Q2 2025 revenue, driven by strength in its prescription products portfolio. Despite the revenue increase, the company posted a net loss of $10.4 million and an operating loss of $8.0 million. Mytesi prescriptions rose 6.5% sequentially, and licensing revenues added modest contributions.

Jaguar Health reported a 6% year-over-year revenue decline in Q1 2025, driven by reduced product sales. Operating and net losses widened compared to the prior year, and non-GAAP recurring EBITDA also declined. Despite the financial setbacks, Mytesi prescription volume grew slightly year-over-year.

Jaguar Health, Inc. reported a net loss of $39.251 million for Q4 2024, an improvement from the $41.901 million loss in Q4 2023. Total revenue increased by 19.8% to $11.689 million, primarily due to higher Mytesi sales and the commercial launch of Gelclair. The company continues to incur significant R&D and sales and marketing expenses as it expands its product pipeline and market access activities.

Jaguar Health reported a revenue of $3.1 million for Q3 2024, representing an increase of 14% compared to Q2 2024 and 11% compared to Q3 2023. The company is advancing its core programs, including the development of crofelemer and the commercial launch of Gelclair.

Jaguar Health reported a combined net revenue of $2.72 million for Q2 2024, representing a 16% increase over Q1 2024 and a 2.0% increase compared to Q2 2023.

Jaguar Health reported a 36% increase in net revenue compared to Q1 2023, reaching $2.7 million, driven by sales of Mytesi® and Canalevia®-CA1. However, the loss from operations also increased to $8.1 million.

Jaguar Health reported a decrease in net revenue for Q1 2023 compared to both Q4 2022 and Q1 2022, but the loss from operations improved over the same period. The company is focusing on patient voice in the HIV community and preparing for the introduction of crofelemer to the market for cancer therapy-related diarrhea.

Jaguar Health reported a 57% increase in prescription product net revenue for Q4 2022 compared to Q4 2021, reaching $3.3 million. The growth was attributed to the continued success of Mytesi and the introduction of Canalevia-CA1. The company is focused on expanding clinical trials and exploring new indications for crofelemer.

Jaguar Health reported a combined net revenue of approximately $3.1 million for Mytesi® and Canalevia®-CA1 in Q3 2022, representing an increase of 8.2% over Q2 2022 and 412% over Q3 2021.

Jaguar Health reported a 112% increase in Mytesi net revenue compared to Q1 2021, reaching $2.6 million, and Canalevia-CA1 is now commercially available.

Jaguar Health reported increased Mytesi net revenue in Q4 2021, driven by the transition to a closed network of specialty pharmacies.

Jaguar Health reported their Q3 2021 financial results, noting a 7.6% increase in Mytesi prescription volume compared to Q2 2021. The company is transitioning to a closed specialty pharmacy network by the end of 2021 as part of their market access strategy.

Jaguar Health reported its first quarter 2021 financial results, highlighting a 250% increase in Mytesi gross sales and a 43% increase in net sales.

Jaguar Health, Inc. reported its financial results for the year ended December 31, 2020, with Mytesi net sales reaching approximately $9.3 million and gross sales at approximately $20.4 million, marking increases of 64% and 148%, respectively, compared to the previous year. The company's net loss for the year was $33.8 million, a decrease from the $38.5 million loss in 2019.

Jaguar Health reported third quarter Mytesi net sales of approximately $2.8 million and gross sales of approximately $6.3 million. The increase in sales coincided with enhancements to the Mytesi patient access program, NapoCares™.

Jaguar Health reported its Q2 2020 financial results, featuring a significant increase in Mytesi net product revenue to $3.2 million, up from $1.7 million in Q2 2019. The company experienced a reduced net loss of $9.2 million compared to $16.7 million in the same quarter last year, driven by increased Mytesi list price and decreased operating expenses.

Jaguar Health's Mytesi net sales were approximately $0.8 million, and Mytesi gross (non-GAAP) sales were approximately $1.3 million, a decrease of 45% and 39%, respectively, over the first quarter of 2019. Total Mytesi prescription volume increased 16% compared to Q1 2019. The net loss was $7.9 million, compared to a net loss of $8.3 million in the first quarter of 2019.

Jaguar Health reported strong Mytesi sales growth in 2019 and is planning to initiate three clinical trials in the second half of 2020, subject to additional financing.